Go Deep
Citius Oncology, Inc.
Citius Oncology, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,211 | -1.6 | 1.95 | 0.25 | 70.66 |
| Oct 2026 | 23,872 | -1.6 | 2.01 | 0.25 | 72.73 |
| Oct 2026 | 22,294 | -1.5 | 1.86 | 0.25 | 67.36 |
| Oct 2026 | 22,429 | -1.4 | 1.76 | 0.25 | 63.62 |
| Oct 2026 | 22,315 | -1.5 | 1.83 | 0.25 | 66.24 |
| Oct 2026 | 22,318 | -1.5 | 1.83 | 0.25 | 66.03 |
Citius Oncology, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,493,788.0 | 1,667,298.0 | 3,944,111.0 | 0.0 |
| Net Profit | -8,923,846.0 | -26,609,695.0 | -5,534,069.0 | -4,996,656.0 |
| EPS | -0.1 | -0.3 | -0.1 | — |
Citius Oncology, Inc. Revenue & Profit: Last 4 Years
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -24,761,369.0 | -21,148,747.0 | -12,697,241.0 | -5,432,599.0 |
| EPS | -0.3 | -0.3 | -0.2 | -0.1 |
Citius Oncology, Inc. Balance Sheet
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Total Assets | 100,942,881.0 | 84,368,878.0 | 47,734,895.0 | 42,690,182.0 |
| Total Liabilities | 56,076,650.0 | 38,228,539.0 | 22,199,235.0 | 6,422,781.0 |
| Total Equity | 44,866,231.0 | 46,140,339.0 | 25,535,660.0 | 36,267,401.0 |
Owes vs Owns
Citius Oncology, Inc. owed $0.64 for every $1 it owned in Jun 2026, up from $0.15 in Sep 2022.
| Period | Jun 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.64× | 0.56× | 0.45× | 0.47× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Citius Oncology, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Sep 2025
Cash & short-term investments 3.9%Inventory 22.1%Intangible assets 72.7%Other assets 1.3%
How it's funded — Sep 2025
Long-term debt 3.8%Payables 13.1%Other liabilities 38.7%Shareholders' equity 44.4%
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3.9 | 0.0 | 0.0 | 0.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 22.3 | 8.3 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 73.4 | 73.4 | 40.0 | 40.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.3 | 2.7 | 7.7 | 2.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 3.8 | 3.8 | 0.0 | 0.0 |
| Payables | 13.2 | 3.7 | 1.3 | 0.1 |
| Other liabilities | 39.0 | 30.7 | 20.9 | 6.3 |
| Shareholders' equity | 44.9 | 46.1 | 25.5 | 36.3 |
| Net tangible assets | -28.5 | -27.3 | -14.5 | -3.7 |
Citius Oncology, Inc. Cash Flow
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Operating Activities | -5,492,046.0 | 126,353.0 | 0.0 | 0.0 |
| Investing Activities | -5,750,000.0 | -5,000,000.0 | 0.0 | — |
| Financing Activities | 15,166,842.0 | 4,873,759.0 | 0.0 | — |